Tessera Therapeutics valuation, funding and investors

Tessera Therapeutics works in genome engineering technology development, based in Somerville, United States. Founded in 2018, it has about 340 employees.

Biotechnology Grant

VALUATION · TODAY

$420M −14% after Series C

Range $206M – $1.80B · Grade D

TODAY

+12 MO

$2.00B

$4.00B

$6.00B

2019

2020

2021

2022

2023

2024

2025

2026

2027

Series B $230M

Series C $300M

ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then

HEADCOUNT · TODAY210 employees

−3%6m growth

−29%1y growth

−40%2y growth

250

500

Data from Jan 2021

TODAY

Predicted in 1 yr $361M −14% vs today

Predicted next raise $437M if a round comes

Winding-down probability 97%

Last round: Series C · $300M · Apr 2022
Valuation at last round: $2.99B · implied
Headcount: 210 · shrinking
Grade: D
Founded: 2018

How VCMC values companies →

Tessera Therapeutics valuation today

VCMC values Tessera Therapeutics at $420M today, with a range of $206M to $1.8B and a grade of D. The valuation starts from its last funding round, a Series C round in Apr 2022.

Valuation by date (109 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

Tessera Therapeutics: valuation by date, as the model would have shown it on each date
Date	Valuation	Range	Predicted in 1 yr	Phase	Headcount	Trend	Grade	Winding-down probability
1 Jan 2018	$9.05M	$3.29M – $24.9M	$12.4M (+37%)	before first round	–	unknown	D	0%
1 Feb 2018	$9.29M	$3.38M – $25.5M	$12.7M (+37%)	before first round	–	unknown	D	0%
1 Mar 2018	$9.52M	$3.47M – $26.2M	$13.1M (+37%)	before first round	–	unknown	D	0%
1 Apr 2018	$9.78M	$3.56M – $26.9M	$13.4M (+37%)	before first round	–	unknown	D	0%
1 May 2018	$10.0M	$3.65M – $27.6M	$13.8M (+37%)	before first round	–	unknown	D	0%
1 Jun 2018	$10.3M	$3.75M – $28.3M	$14.1M (+37%)	before first round	–	unknown	D	0%
1 Jul 2018	$10.6M	$3.85M – $29.1M	$14.5M (+37%)	before first round	–	unknown	D	0%
1 Aug 2018	$10.9M	$3.96M – $29.9M	$14.7M (+35%)	before first round	–	unknown	D	0%
1 Sep 2018	$11.2M	$4.06M – $30.7M	$14.8M (+32%)	before first round	–	unknown	D	0%
1 Oct 2018	$11.5M	$4.17M – $31.5M	$14.9M (+30%)	before first round	–	unknown	D	0%
1 Nov 2018	$11.8M	$4.28M – $32.3M	$15.1M (+28%)	before first round	–	unknown	D	0%
1 Dec 2018	$12.1M	$4.40M – $33.2M	$15.2M (+26%)	before first round	–	unknown	D	0%
1 Jan 2019	$12.4M	$4.52M – $34.1M	$15.3M (+24%)	before first round	–	unknown	D	0%
1 Feb 2019	$12.7M	$4.64M – $35.0M	$15.5M (+21%)	before first round	–	unknown	D	0%
1 Mar 2019	$13.1M	$4.75M – $35.9M	$15.6M (+19%)	before first round	–	unknown	D	0%
1 Apr 2019	$13.4M	$4.88M – $36.8M	$15.7M (+17%)	before first round	–	unknown	D	0%
1 May 2019	$13.8M	$5.01M – $37.8M	$15.9M (+15%)	before first round	–	unknown	D	0%
1 Jun 2019	$14.1M	$5.15M – $38.8M	$16.0M (+13%)	before first round	–	unknown	D	0%
1 Jul 2019	$14.5M	$5.28M – $39.8M	$16.2M (+11%)	before first round	–	unknown	D	0%
1 Aug 2019	$14.7M	$5.33M – $40.2M	$16.3M (+11%)	before first round	–	unknown	D	0%
1 Sep 2019	$14.8M	$5.38M – $40.6M	$16.5M (+11%)	before first round	–	unknown	D	0%
1 Oct 2019	$14.9M	$5.43M – $41.0M	$16.6M (+11%)	before first round	–	unknown	D	0%
1 Nov 2019	$15.1M	$5.48M – $41.4M	$16.8M (+11%)	before first round	–	unknown	D	0%
1 Dec 2019	$15.2M	$5.53M – $41.7M	$16.9M (+11%)	before first round	–	unknown	D	0%
1 Jan 2020	$15.3M	$5.58M – $42.1M	$17.1M (+11%)	before first round	–	unknown	D	0%
1 Feb 2020	$15.5M	$5.63M – $42.5M	$17.2M (+11%)	before first round	–	unknown	D	0%
1 Mar 2020	$15.6M	$5.68M – $42.9M	$17.4M (+11%)	before first round	–	unknown	D	0%
1 Apr 2020	$15.7M	$5.73M – $43.3M	$17.5M (+11%)	before first round	–	unknown	D	0%
1 May 2020	$15.9M	$5.78M – $43.6M	$17.7M (+11%)	before first round	–	unknown	D	0%
1 Jun 2020	$16.0M	$5.84M – $44.0M	$17.9M (+11%)	before first round	–	unknown	D	0%
1 Jul 2020	$16.2M	$5.89M – $44.4M	$18.0M (+11%)	before first round	–	unknown	D	0%
1 Aug 2020	$16.3M	$5.94M – $44.8M	$18.2M (+11%)	before first round	–	unknown	D	0%
1 Sep 2020	$16.5M	$6.00M – $45.2M	$18.3M (+11%)	before first round	–	unknown	D	0%
1 Oct 2020	$16.6M	$6.05M – $45.6M	$18.5M (+11%)	before first round	–	unknown	D	0%
1 Nov 2020	$16.8M	$6.11M – $46.1M	$18.7M (+11%)	before first round	–	unknown	D	0%
1 Dec 2020	$16.9M	$6.16M – $46.5M	$18.8M (+11%)	before first round	–	unknown	D	0%
1 Jan 2021	$18.7M	$6.80M – $51.3M	$20.8M (+11%)	before first round	28	unknown	D	0%
13 Jan 2021	$1.6B	$1.1B – $3.8B	$2.5B (+50%)	after a round	28	unknown	C	0%
1 Feb 2021	$1.7B	$1.1B – $3.8B	$2.5B (+47%)	after a round	28	unknown	C	0%
1 Mar 2021	$1.7B	$1.1B – $3.8B	$2.5B (+42%)	after a round	28	unknown	C	0%
1 Apr 2021	$1.8B	$1.1B – $3.8B	$2.5B (+37%)	after a round	28	flat	C	0%
1 May 2021	$1.9B	$1.1B – $3.8B	$2.5B (+33%)	after a round	28	flat	C	0%
1 Jun 2021	$1.9B	$1.1B – $3.8B	$2.5B (+28%)	after a round	28	flat	C	0%
1 Jul 2021	$2.0B	$1.1B – $3.8B	$2.5B (+24%)	after a round	28	flat	C	0%
1 Aug 2021	$2.1B	$1.1B – $3.8B	$2.5B (+20%)	after a round	28	flat	C	0%
1 Sep 2021	$2.1B	$1.1B – $3.8B	$2.5B (+16%)	after a round	28	flat	C	0%
1 Oct 2021	$2.2B	$1.1B – $3.8B	$2.5B (+12%)	after a round	28	flat	C	0%
1 Nov 2021	$2.3B	$1.1B – $3.8B	$2.5B (+8%)	after a round	28	flat	C	0%
1 Dec 2021	$2.4B	$1.1B – $3.8B	$2.5B (+5%)	after a round	28	flat	C	0%
1 Jan 2022	$2.4B	$1.1B – $3.8B	$2.5B (+1%)	after a round	28	flat	C	0%
1 Feb 2022	$2.5B	$1.0B – $3.8B	$2.5B (0%)	after a round	28	flat	C	0%
1 Mar 2022	$3.8B	$1.7B – $5.7B	$3.8B (0%)	after a round	190	growing	C	0%
1 Apr 2022	$3.8B	$1.7B – $5.7B	$3.8B (0%)	after a round	190	growing	C	0%
20 Apr 2022	$3.0B	$2.1B – $5.5B	$3.9B (+30%)	after a round	190	growing	B	0%
1 May 2022	$3.0B	$2.1B – $5.5B	$3.9B (+29%)	after a round	190	growing	B	0%
1 Jun 2022	$3.1B	$2.1B – $5.5B	$3.9B (+26%)	after a round	190	growing	B	0%
1 Jul 2022	$3.2B	$2.1B – $5.5B	$3.9B (+23%)	after a round	190	growing	B	0%
1 Aug 2022	$3.2B	$2.1B – $5.5B	$3.9B (+21%)	after a round	190	growing	B	0%
1 Sep 2022	$3.3B	$2.1B – $5.5B	$3.9B (+18%)	after a round	190	growing	B	0%
1 Oct 2022	$3.4B	$2.1B – $5.5B	$3.9B (+15%)	after a round	190	growing	B	0%
1 Nov 2022	$3.4B	$2.1B – $5.5B	$3.9B (+13%)	after a round	190	unknown	B	0%
1 Dec 2022	$3.5B	$2.1B – $5.5B	$3.9B (+11%)	after a round	190	unknown	B	0%
1 Jan 2023	$3.9B	$2.3B – $6.1B	$4.3B (+11%)	after a round	300	growing	B	0%
1 Feb 2023	$4.0B	$2.3B – $6.1B	$4.3B (+8%)	after a round	300	growing	B	0%
1 Mar 2023	$4.1B	$2.3B – $6.1B	$4.3B (+5%)	after a round	300	growing	B	0%
1 Apr 2023	$4.2B	$2.3B – $6.1B	$4.3B (+2%)	after a round	300	growing	B	0%
1 May 2023	$4.3B	$2.3B – $6.1B	$4.3B (0%)	after a round	300	growing	B	0%
1 Jun 2023	$4.3B	$2.3B – $6.1B	$4.3B (0%)	after a round	300	growing	B	0%
1 Jul 2023	$4.3B	$2.4B – $6.1B	$4.3B (0%)	after a round	300	growing	B	0%
1 Aug 2023	$4.3B	$2.4B – $6.1B	$4.3B (0%)	after a round	300	growing	B	0%
1 Sep 2023	$4.3B	$2.4B – $6.1B	$4.3B (0%)	after a round	300	growing	B	0%
1 Oct 2023	$4.3B	$1.8B – $6.1B	$4.3B (0%)	after a round	300	unknown	C	0%
1 Nov 2023	$4.3B	$1.7B – $6.1B	$4.3B (0%)	after a round	300	unknown	C	0%
1 Dec 2023	$4.3B	$1.7B – $6.1B	$4.3B (0%)	after a round	300	unknown	C	0%
1 Jan 2024	$4.3B	$1.6B – $6.1B	$4.3B (0%)	after a round	300	unknown	C	0%
1 Feb 2024	$4.3B	$1.5B – $6.1B	$4.3B (0%)	after a round	300	unknown	C	0%
1 Mar 2024	$4.6B	$2.2B – $6.5B	$4.6B (0%)	after a round	390	up	B	0%
1 Apr 2024	$4.6B	$2.2B – $6.5B	$4.6B (0%)	after a round	390	up	B	0%
1 May 2024	$4.6B	$2.0B – $6.5B	$4.6B (0%)	after a round	390	up	B	0%
1 Jun 2024	$4.6B	$1.9B – $6.5B	$4.5B (0%)	after a round	390	up	C	0%
1 Jul 2024	$4.6B	$1.9B – $6.5B	$4.5B (0%)	after a round	390	up	C	0%
1 Aug 2024	$3.1B	$1.1B – $6.0B	$2.4B (-22%)	after a round	350	down	C	54%
1 Sep 2024	$3.1B	$1.1B – $6.0B	$2.4B (-23%)	after a round	350	down	C	54%
1 Oct 2024	$3.1B	$1.0B – $6.1B	$2.3B (-23%)	after a round	350	down	C	54%
1 Nov 2024	$2.7B	$952M – $6.0B	$1.9B (-29%)	after a round	340	down	C	70%
1 Dec 2024	$2.6B	$906M – $6.1B	$1.8B (-29%)	after a round	340	down	C	70%
1 Jan 2025	$2.6B	$861M – $6.1B	$1.8B (-30%)	after a round	340	down	C	70%
1 Feb 2025	$2.5B	$819M – $6.2B	$1.8B (-31%)	after a round	340	down	D	70%
1 Mar 2025	$2.5B	$782M – $6.2B	$1.7B (-31%)	after a round	340	down	D	70%
1 Apr 2025	$2.4B	$743M – $6.2B	$1.7B (-32%)	after a round	340	down	D	70%
1 May 2025	$2.2B	$707M – $6.3B	$1.5B (-31%)	after a round	340	down	D	70%
1 Jun 2025	$2.2B	$672M – $6.3B	$1.5B (-31%)	after a round	340	down	D	70%
1 Jul 2025	$2.2B	$643M – $6.3B	$1.6B (-29%)	after a round	347	down	D	65%
1 Aug 2025	$1.9B	$598M – $6.1B	$1.3B (-32%)	after a round	315	down	D	74%
1 Sep 2025	$1.5B	$561M – $6.1B	$907M (-38%)	after a round	296	down	D	97%
1 Oct 2025	$1.5B	$534M – $6.1B	$984M (-36%)	after a round	296	down	D	89%
1 Nov 2025	$1.6B	$506M – $6.0B	$1.1B (-34%)	after a round	292	down	D	82%
1 Dec 2025	$1.6B	$481M – $6.0B	$1.1B (-33%)	after a round	292	down	D	79%
1 Jan 2026	$1.6B	$457M – $6.0B	$1.0B (-34%)	after a round	292	down	D	79%
1 Feb 2026	$1.5B	$435M – $6.0B	$1.0B (-34%)	after a round	292	down	D	79%
1 Mar 2026	$1.6B	$415M – $5.9B	$1.1B (-32%)	after a round	292	down	D	73%
1 Apr 2026	$749M	$369M – $2.5B	$456M (-39%)	after a round	216	shrinking	C	97%
1 May 2026	$683M	$349M – $2.1B	$453M (-34%)	after a round	210	shrinking	C	97%
1 Jun 2026	$654M	$332M – $2.0B	$453M (-31%)	after a round	210	shrinking	C	97%
1 Jul 2026	$627M	$316M – $2.0B	$453M (-28%)	after a round	210	shrinking	C	97%
1 Aug 2026	$601M	$300M – $1.9B	$453M (-25%)	after a round	210	shrinking	C	97%
1 Sep 2026	$575M	$285M – $1.9B	$452M (-21%)	after a round	210	shrinking	C	97%
1 Oct 2026	$552M	$272M – $1.8B	$452M (-18%)	after a round	210	shrinking	C	97%
24 Oct 2026	$420M	$206M – $1.8B	$361M (-14%)	after a round	210	shrinking	D	97%

Key facts about Tessera Therapeutics

Founded: 2018
Headquarters: Somerville, United States
Employees: about 340 -13% in a year
Total raised: $571M
Funding rounds: 3
Last round: Grant Oct 2025

Tessera Therapeutics was founded in 2018 by Geoffrey von Maltzahn, Jacob Rubens and Noubar Afeyan.

Tessera Therapeutics funding history

Tessera Therapeutics has 3 funding rounds on record, from Jan 2021 to Oct 2025, $571M in total. None disclosed a valuation.

Grant 8 Oct 2025no round page
Led by Advanced Research Projects Agency for Health.
Sources: globenewswire.com, tesseratherapeutics.com, finance.yahoo.com
$41M
Series C 19 Apr 2022
Led by SoftBank Vision Fund; with Abu Dhabi Investment Authority, Alaska Permanent Fund Corporation, Altitude Life Science Ventures, Artis Ventures, Cormorant Asset Management, Flagship Pioneering, Hanwha Impact, Longevity Vision Fund, March Capital, SALT Fund, T. Rowe Price Associates, Inc..
Sources: alleywatch.com, flagshippioneering.com, globalgenes.org and 1 more
$300M
Series B 12 Jan 2021
Led by SoftBank Vision Fund, Alaska Permanent Fund Corporation, Altitude Life Science Ventures; with Qatar Investment Authority, Flagship Pioneering.
Sources: businesswire.com, journals.sagepub.com
$230M

Tessera Therapeutics investors

14 investors have backed Tessera Therapeutics; Alaska Permanent Fund Corporation, Altitude Life Science Ventures and SoftBank Vision Fund and 1 more led at least one round.

Altitude Life Science Ventures lead, 2 rounds
SoftBank Vision Fund lead, 2 rounds
Advanced Research Projects Agency for Health lead
Flagship Pioneering 2 rounds
Abu Dhabi Investment Authority
Cormorant Asset Management
Longevity Vision Fund
March Capital
Qatar Investment Authority
SALT Fund
T. Rowe Price Associates, Inc.

What Tessera Therapeutics does

Tessera Therapeutics works in biotechnology, with 11 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals.

Tessera Therapeutics is a United States biotechnology company engaged in gene engineering and genetic medicine, with a focus on developing proprietary genome engineering technologies and delivery systems for the treatment of monogenic diseases, oncology, and autoimmune disorders. The company utilizes lipid nanoparticle (LNP) delivery technology to deliver therapeutic RNA Gene Writers to specific tissues, including the liver, hematopoietic stem cells, and T cells. Tessera Therapeutics operates globally and holds FDA Fast Track and Orphan Drug Designations for its in vivo gene editing program for the treatment of Alpha-1 Antitrypsin Deficiency.

Description from Veridion's company data.

Products and services

Genome Engineering Technology Development
Gene Writing Technology Development
RNA Gene Writer Design and Engineering
Lipid Nanoparticle Delivery System Development
Tissue-Targeted Genetic Therapy Delivery
Monogenic Disease Therapeutic Development
Oncology Genetic Medicine Development
Autoimmune Disease Genetic Therapy Development
Patient-Centric Genetic Medicine Solutions
Genetic Disease Therapeutic Development
Genetic Medicine Platform Licensing

Markets

Healthcare
Biotechnology
Pharmaceuticals

Technology

Gene Writing™
Lipid Nanoparticle (LNP) Delivery Technology

Certifications

FDA Fast Track
Orphan Drug Designation

Business model

Business-to-Business

Industry codes (NAICS)

541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match

Questions about Tessera Therapeutics

What is Tessera Therapeutics worth?

Valuation $420M (range $206M to $1.8B), as of 24 Oct 2026.

Has Tessera Therapeutics raised money?

Tessera Therapeutics has 3 funding rounds on record, from Jan 2021 to Oct 2025, $571M in total. None disclosed a valuation.

Who has invested in Tessera Therapeutics?

Alaska Permanent Fund Corporation, Altitude Life Science Ventures, SoftBank Vision Fund, Advanced Research Projects Agency for Health, Flagship Pioneering and Abu Dhabi Investment Authority, and 8 more. Lead investors include Alaska Permanent Fund Corporation, Altitude Life Science Ventures, SoftBank Vision Fund and Advanced Research Projects Agency for Health.

How many people work at Tessera Therapeutics?

About 340, down 13% over the last year. Headcount rose from 28 in Jan 2021 to 390 in Mar 2024, then fell to 210 in May 2026.

What does Tessera Therapeutics do?

Tessera Therapeutics works in biotechnology, with 11 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals. Its main offerings are genome engineering technology development, gene writing technology development and RNA gene writer design and engineering.

When was Tessera Therapeutics founded, and where is it based?

Tessera Therapeutics was founded in 2018 and is based in Somerville, United States. It has about 340 employees, down 13% over the last year.

How we value companies Report an issue